Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180

Inclusion Criteria: * Male and female CHD or CHD equivalent patients * Body mass index (BMI) must be within the range of 20 to 35 kg/m2, * Patient must have been on a stable statin therapy for \>8 weeks prior to first dose except for the statin intolerant patients. Exclusion criteria: * Pregnancy * Significant illness within two weeks prior to dosing. * Triglycerides ≥ 500 mg/dl (5.65 mmol/l) * Uncontrolled hypertension * Any condition that in the opinion of the investigator or the Novartis medical monitor would jeopardize the evaluation of efficacy or safety. * Presence of NYHA Class III or IV chronic heart failure * MI or angioplasty (including stenting), acute coronary syndrome (ACS), unstable angina or arterial embolic disease within 6 months prior to do Other protocol-defined inclusion/exclusion criteria may apply